Chemistry: analytical and immunological testing – Biological cellular material tested
Reexamination Certificate
1999-06-02
2001-05-01
Wallenhorst, Maureen M. (Department: 1743)
Chemistry: analytical and immunological testing
Biological cellular material tested
C436S008000, C436S010000, C436S018000, C436S176000, C436S179000, C435S002000, C252S408100
Reexamination Certificate
active
06225124
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Technical Field
The present invention relates to assaying mean corpuscular volume (MCV) in blood samples; more particularly the invention relates to reagents for, as well as a method of use in, MCV assays using a particle analyzer.
2. Description of Related Art
Automated hematological analyzers are now widely used in the area of clinical examination. As devices for screening patients in medical diagnostic procedures, they are designed for rapid analysis of blood constituents. Such devices can perform the multiple assays of a complete blood count (CBC), including such items as red blood cell (RBC) count, white blood cell (WBC) count, leukocyte classification, hemoglobin concentration (Hb), hematocrit (Ht) and platelet (PLT) count.
The MCV is one among vital items obtained by calculating from these cytometric assay values. The MCV is obtained as the hematocrit divided by the RBC count, that is, the value Ht/RBC, the hematocrit being the percentage of erythrocytes (red blood cells) in a unit volume of whole blood. The MCV, then is the average volume of a single red blood cell, and accordingly it is given in fL, femtoliters, or 10
−15
L.
The hematological analyzers noted above employ flow cytometers. In flow cytometers, a diluted blood sample is discharged into a flow cell at high speed through a very thin nozzle, and the discharging flow from the nozzle is surrounded by the cylindrical flow of a sheathing liquid (laminar flow). By narrowing the laminar flow, the sample flow can thus be focused, to the point at which the flow is essentially a cell-by-cell linear succession. The cells, whose passage in the sample flow is thus controlled by the laminar flow, are then detected optically, by irradiating the flow with a laser beam, as well as electrically, by measuring the resistance or conductivity.
To prepare a whole blood sample for flow-cytometric assay in a hematological analyzer as described above, the sample generally must be treated with an anti-coagulant agent such as an EDTA salt, and diluted with a physiologically isotonic solution.
As diluents for diluting whole blood, there are in general such solutions as physiological saline, Ringer's solution, Locke's solution, and Tyrode's solution. In performing the above-described assays in a hematological analyzer, the foregoing diluents can be used. Ordinarily, however, diluents optimized for individual analyzers are employed.
A basic problem with the current technology in preparing whole blood samples for MCV assay is that the actual MCV changes with post-blood drawing elapsed time. The MCV value that is necessary and important in clinical diagnosis is that which would be obtained immediately after the blood sample is drawn, that is, that value which corresponds to the MCV of the original blood.
In practice, the MCV value as part of a CBC is not measured until as much as 72 hours have passed following drawing of the blood sample. At that point, however, blood samples as such no longer yield suitable MCV assay values. After the blood is drawn, the RBCs in the sample swell, such that MCV values measured with the post-drawing elapse of time are progressively larger than the original RBC mean volume. The original MCV is the actual measurement diagnostically required.
Japanese Pat. Publ. 8-33388 (1996), Japanese Pat. Publ. 7-82010 (1995), and Japanese Laid Open Pat. 8-122327 (1996) disclose various aqueous solutions containing nonionic surfactants. Nevertheless, whichever of these solutions is used as a flow-cytometer sheathing liquid, and the nonionic surfactants are added for eliminating air bubbles within the flow chamber.
Furthermore, Japanese Pat. Publ. 1-33780 (1989) discloses a diluent into which a nonionic surfactant has been added to neutralize the effect on erythrocytes of antiseptic agents, ultimately with the object of restraining post-dilution change in the measured MCV due to the antiseptic agents. Nevertheless, Japanese Pat. Publ. 1-33780 does not disclose a method of restraining change in measured MCV due to the passage time after drawing blood samples.
It would be an important advance in the art if a means could be found to bring about consistency with blood sample original values in hematocrit and RBC count measurements made up to 72 hours after the blood is drawn.
SUMMARY OF THE INVENTION
The present invention compels a blood sample to yield an MCV value assayed at elapsed time after the sample is drawn to be remarkably consistent with the original MCV value of the sample, that is, the immediate post-drawing MCV value.
A reagent in accordance with the invention is a blood sample aqueous diluting solution that includes a small amount of a predetermined surfactant added within a limited range of concentration. The osmotic pressure of the reagent is adjusted with a suitable substance to be within a predetermined range.
A reagent for the present invention is an aqueous solution including a nonionic surfactant, and a salt or suitable substance for adjusting osmotic pressure (&pgr;) to be approximately 150-400 mOsm/kg.
Preferably the osmotic pressure (&pgr;) of the reagent is approximately 230-350 mOsm/kg; especially preferable is an osmotic pressure (&pgr;) of approximately 260-320 mOsm/kg. As examples of nonionic surfactants in an embodiment of the present invention, any of the following can be used.
wherein R indicates one of an alkyl chain, an alkenyl chain and an alkynyl chain, respectively having 12-24 carbons; and n, n
1
+n
2
+n
3
, and n
1
+n
2
+n
3
+n
4
+n
5
+n
6
indicate an integer 5-70.
In a preferred embodiment of the present invention, the nonionic surfactant includes at least one of an alkyl chain, an alkenyl chain and an alkynyl chain, respectively having 12-24 carbons.
The nonionic surfactant preferably includes a polyoxyethylene chain having an ethylene oxide molar addition number of 5-70.
As concrete examples, any of the following nonionic surfactants can be used in an embodiment in accordance with the present invention.
a) Polysorbate-80 (oleate esters of sorbitan plus 20 moles PEG), Croda Co.'s “Crillet 4.”
b) Steareth-20 (Stearyl alcohol+PEG 20), Croda Co.'s “Volpo S-20.”
c) PEG-60 Almond Glycerides (Almond mono and diglycerides with 60 moles PEG), Croda Co.'s “Crovol A-70.”
d) PEG-23 Oleate (oleic acid plus PEG23 ester), Croda Co.'s “Crodet 0 23.”
One further preferable nonionic surfactant is Oleth-20 (polyoxyethylene [20] oleyl ether). This surfactant contains a polyoxyethylene oleyl ether mixture wherein the average number of oxyethylene units per molecule is approximately 20.
CTFA Names is the source of the names for the substances noted above.
It should be apparent that within the scope of the present invention, mixtures of nonionic surfactants as herein defined could also be used. It should also apparent that commercially available nonionic surfactants are suitable for this invention, provided that they otherwise conform to the parameters given herein. It is well known that these commercially available nonionic surfactants are not chemically pure materials. Consequently, concomitant introduction of related nonionic structures and extraneous materials into a reagent in accordance with the invention is within its scope, on the condition that the foregoing parameters are satisfied.
It is particularly important that the surfactants or mixtures thereof are transparent in the salt solution. The nonionic surfactants must be completely soluble in water to yield a clear solution at a minimum weight concentration of 0.1%.
The concentration of the given nonionic surfactants for inclusion in the reagent can be suitably determined according to the osmotic pressure and the composition of the salt solution as the solvent. In general, however, the nonionic surfactants can be employed at a low concentration in the range of approximately 0.0005%-0.5%. A preferable concentration is in the range of approximately 0.001%-0.1%, and most preferably is in the range of approximately 0.005%-0.05%.
I
Hamaguchi Yukio
Houwen Berend
Mast Rolf
Uchihashi Kinya
Shinjyu Intellectual Property Firm
Sysmex Corporation
Wallenhorst Maureen M.
LandOfFree
Diluting reagent and method compelling time-independent... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diluting reagent and method compelling time-independent..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diluting reagent and method compelling time-independent... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2541163